Holdings
Bellevue Group AG
As of Sep 30, 2026, Bellevue Group AG reported 143 positions worth US$4.64B. Largest: Amgen Inc., Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Amgen Inc. | 862K | US$363M | +10,140 | Sep 30, 2026 |
| Gilead Sciences, Inc. | 2.15M | US$321M | −8,080 | Sep 30, 2026 |
| Vertex Pharmaceuticals Incorporated | 579K | US$302M | −102 | Sep 30, 2026 |
| argenx SE | 291K | US$279M | −10,493 | Sep 30, 2026 |
| Regeneron Pharmaceuticals, Inc. | 280K | US$212M | +122K | Sep 30, 2026 |
| Revolution Medicines, Inc. | 999K | US$205M | −49,064 | Sep 30, 2026 |
| Insmed Incorporated | 1.51M | US$172M | +115K | Sep 30, 2026 |
| Viridian Therapeutics, Inc. | 7.11M | US$146M | +377K | Sep 30, 2026 |
| Oruka Therapeutics, Inc. | 1.64M | US$137M | −16,131 | Sep 30, 2026 |
| Biogen Inc. | 598K | US$135M | +598K | Sep 30, 2026 |